MedTrace Logo

Methylene Blue for the Treatment of Septic Shock

NCT06532240 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-02-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of methylene blue among adult patients with septic shock.

Conditions

  • Septic Shock

Interventions

DRUG

Methylene Blue

Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution.The patient will receive Methylene Blue bolus with a dose of 1 mg/kg (Ideal Body Weight) over 30 minutes,followed by 0.25mg/kg/h as a continuous infusion for 6 hours for 5 days or discontinution of norepinephrine or until ICU discharge, whichever occurred first.

DRUG

Placebo

An identical volume of 5% dextrose solution from the placebo drug bag will be administered to patients using the same protocol as intervention arm.

Sponsors & Collaborators

  • Northern Jiangsu People's Hospital

    lead OTHER

Principal Investigators

  • Qingquan Lyu, Master · Northern Jiangsu People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-05
Primary Completion
2025-10-24
Completion
2025-10-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06532240 on ClinicalTrials.gov